BNP correlated most strongly with NYHA heart failure class in outpatients, outperforming C-ANP and N-ANP, supporting BNP as the preferred biomarker for monitoring treatment response.
BNP winsBNP correlated most strongly with functional heart failure class in outpatients, confirming it as the preferred monitoring biomarker over ANP variants
What the researchers found
BNP correlated most strongly with NYHA heart failure classification and treatment response in outpatients, outperforming C-terminal ANP and N-terminal ANP as a monitoring biomarker.
Why it matters
Monitoring heart failure treatment effectiveness requires reliable biomarkers. This study confirms BNP's superiority for outpatient monitoring, guiding clinical practice and laboratory test selection.
How the study worked
Cross-sectional study comparing C-ANP, N-ANP, and BNP levels against NYHA class in outpatient heart failure patients. Biomarker performance assessed for treatment monitoring utility.
What this study cannot tell us
Cross-sectional design; serial monitoring over time would provide stronger evidence. Specific NYHA-BNP correlation coefficients not detailed. Treatment heterogeneity in outpatient population.
How to read the evidence
Moderate evidence from a comparative biomarker study with clinical severity correlation in outpatient heart failure.
When this study was published
Published in 2002. BNP/NT-proBNP-guided heart failure management is now recommended in clinical guidelines.
The bigger picture
Biomarker-guided heart failure management — adjusting treatment based on BNP trends rather than just symptoms — has the potential to improve outcomes by enabling more precise therapy adjustment.
Questions still open
- Should BNP targets guide heart failure drug dosing?
- Does serial BNP monitoring reduce heart failure hospitalizations?
- Can BNP distinguish between stable and deteriorating outpatient heart failure?
Common questions
Which blood test is best for monitoring heart failure?
Should heart failure patients get regular BNP tests?
Read the original research
The potential of brain natriuretic peptide as a biomarker for New York Heart Association class during the outpatient treatment of heart failure.
Journal of cardiac failure, 8(3), 149-54
Citation
Lee, Shang-Chiun; Stevens, Tracy L; Sandberg, Sharon M; Heublein, Denise M; Nelson, Susan M; Jougasaki, Michihisa; Redfield, Margaret M; Burnett, John C. (2002). The potential of brain natriuretic peptide as a biomarker for New York Heart Association class during the outpatient treatment of heart failure.. Journal of cardiac failure, 8(3), 149-54.